This study aimed to determine the effect of insulin-like growth factor-I (IGF-I) on early antral bovine follicular development, and the expression of insulin-like growth factor-binding protein-2 (IGFBP-2). Antral follicles separated into three different size groups were cultured for 6 days in medium supplemented with either a low (10 ng/ml) or high (1 mg/ml) dose of human recombinant IGF-I. Oestradiol production by follicles in all size ranges, cultured in the presence of the high concentration of IGF-I, significantly increased by day 6 (P < 0.05). Follicles in the smallest size range, 165 -215 mm, cultured in a high dose of IGF-I, were found to be significantly increased in size (P < 0.01). Oocyte health of the largest follicles (281-380 mm) was significantly improved by the addition of IGF-I to the culture medium. mRNA expression of IGFBP-2 was decreased in the granulosa cells of follicles, size range 216 -280 mm, cultured with a high dose of IGF-I (P < 0.05). Granulosa cells (P < 0.05) and oocytes (P < 0.01) of the largest follicles (281-380 mm) showed a decrease in IGFBP-2 expression (protein) when cultured in the control and low-IGF-I treatment groups. Therefore, the response of a bovine follicle to IGF-I is both dose and stage dependent. This work supports a role for IGF-I in modulating somatic and germ-cell maturation and development in early antral follicles. Furthermore, the inverse relationship between the level of IGF-I stimulation and IGFBP-2 expression suggests a local regulatory system modulating IGF-I availability.
Introduction
The insulin-like growth factor (IGF) system has already been shown to play a key role in ovarian function (Giudice 1992 , Poretsky et al. 1999 . During follicle growth, IGF works in synergy with gonadotrophins (follicle-stimulating hormone (FSH) and luteinising hormone (LH)) to regulate proliferation and differentiation of granulosa and theca cells , Gutierrez et al. 1997 . Furthermore, an absolute requirement for IGF-I in female fertility has been demonstrated in experiments using IGF-I knockout mice, whose follicles were arrested at the late preantral/early antral stage and failed to respond to gonadotrophins (Baker et al. 1996 , Zhou et al. 2000 . In cattle, there does not seem to be an absolute requirement for IGF-I in antral formation, but it has been shown to be important at the antral stage of follicle development, where it is involved in the regulation of follicle growth, stimulation of somatic cell proliferation, and oestrogen, as well as progesterone biosynthesis (Armstrong & Webb 1997 , Webb et al. 1999 . Nuclear maturation in the oocytes of cattle (Lorenzo et al. 1994) and pigs (Sirotkin et al. 2000) is enhanced by IGF-I; however, addition of IGF-I was not shown to improve nuclear or cytoplasmic maturation of sheep oocytes (Guler et al. 2000) . Recent work has also outlined the beneficial effects of IGF-I in early follicle growth , Louhio et al. 2000 , Zhao et al. 2001 , Itoh et al. 2002 . However, although IGF has a stimulatory effect in early follicle growth, work by McCaffery et al. (2000) highlighted the importance of regulatory mechanisms, showing that inappropriate exposure of bovine preantral follicles to IGF-I has a detrimental effect on oocyte development.
IGF-I expression remains controversial, with reports demonstrating both its presence, at very low levels (Yuan et al. 1998) , and absence (Armstrong et al. 2000) . However, intense expression of mRNA encoding IGF-II in thecal tissue of bovine ovarian follicles has been detected (Armstrong & Webb 1997) , and a similar spatial distribution has been described in sheep (Perks et al. 1995) . In the cow, IGF-II has been shown to be the principal intrafollicular IGF ligand (Armstrong et al. 2000) . IGFbinding proteins (IGFBPs) regulate the availability of IGFs to their target cells by either inhibiting or potentiating their action (Giudice 1992) . IGFBPs can sequester extracellular IGFs and hence reduce the bioavailability of IGF. However, two mechanisms by which facilitation of the IGFs can be increased is by the activity of specific IGFBP proteases and changes in the expression of the IGFBPs (Giudice 1992) . At present, mRNA encoding IGFBP-2, -5 has been detected in bovine follicles (Armstrong & Webb 1997 , Armstrong et al. 1998 , and IGFBP-2, -4 and -5 mRNA have been found in the ovine follicle . IGFBP-2 mRNA has been found in the granulosa cells and oocytes of bovine preantral and early antral follicles (Armstrong et al. 2002) , as well as the granulosa cells of larger antral follicles (1 -8 mm) (Armstrong et al. 1998) . Furthermore, immunoreactive IGFBP-2 has been detected around granulosa cells from bovine follicles at the preantral stage (Armstrong et al. 2002) , indicating that IGFBP-2 may be important in regulating bioavailability during early stages of follicular development.
The regulation of IGF-I bioavailability by IGFBPs is important for normal follicle and oocyte development. The detection of IGF-I binding in bovine preantral follicles (Wandji et al. 1992) , coupled with the expression of type 1 IGF receptor and IGFBP-2 mRNA from the preantral stage (Spicer & Echternkamp 1995 , Perks et al. 1999 , Armstrong et al. 2002 , suggests a role for the IGF system in early follicle development. Therefore, it is important to understand the mechanisms involved in regulating the expression of IGFBPs and hence the availability of IGF to its receptors at different stages of growth. Changes in the effects of IGF-I , Gutierrez et al. 1997 ) and the expression of IGFBPs from early to late follicle development further support the view that the need for IGF-I stimulation is dependent on the stage of the developing follicle. The present study aimed to investigate the effect of IGF-I on early antral follicular development and the expression of IGFBP-2. In particular, follicle growth, oestradiol production and the expression of IGFBP-2 during the crucial transition phase from late preantral to early antral stage will be investigated.
Materials and Methods

Antral follicle isolation
Bovine ovaries from random stages of the oestrous cycle were obtained from a local abattoir and transported to the laboratory. During transit, they were maintained at 25-30 8C in M199 (HEPES-buffered) medium (Gibco BRL, Life Technologies, Paisley, UK) supplemented with sodium pyruvate (2 mM), glutamine (2 mM), BSA (3 mg/ml), penicillin G (75 mg/ml) and streptomycin (50 mg/ml) (all chemicals from Sigma unless otherwise stated). Upon arrival at the laboratory, the ovaries were placed under a laminar flow hood, rinsed in 70% alcohol and kept warm (37 8C) in an incubator. Underneath a laminar flow hood, fine slices (, 1 mm wide) of ovarian cortex were taken with a scalpel and placed in dissection medium (Leibovitz's medium (Gibco BRL)) supplemented with sodium pyruvate (2 mM), glutamine (2 mM), Fraction V BSA (3 mg/ml), penicillin G (75 mg/ml) and streptomycin (50 mg/ml), and maintained at 37 8C. Early antral follicles were isolated from the cortical slices under a dissecting microscope with 25G needles and sorted into three size groups (small (165-215 mm), medium (216-280 mm) and large (281-380 mm)). Approximately 40 follicles were isolated on each culture day. Follicles of a normal shape, with an intact basement membrane and no obvious signs of degeneration, were selected for culture. The time taken for collection of ovaries from the abattoir to the start of the culture period was a maximum of 6 h.
Follicle culture
Follicles were cultured individually in 96-well (V-shaped bottom) plates (Bibby Sterlin, Stone, UK) in 250 ml culture medium (McCoy's 5A Medium) with bicarbonate supplemented with HEPES (20 mM), Fraction V BSA (0.1%), L-glutamine (3 mM), penicillin (100 IU/ml), streptomycin (0.1 mg/ml), transferrin (2.5 mg/ml), selenium (4 ng/ml), androstenedione (10 27 M), insulin (10 ng/ml) and L-ascorbic acid sodium salt (50 mg/ml), all obtained from Sigma. The culture medium described in this current study was originally developed for the culture of ovine and bovine granulosa cells , Gutierrez et al. 1997 , and was subsequently modified for the culture of bovine preantral follicles , McCaffery et al. 2000 , Thomas et al. 2001 . Control groups were cultured in culture medium alone, whereas treatment groups were cultured in culture medium supplemented with either 10 ng/ml or 1 mg/ml human recombinant IGF-I (Sigma). The lower dose of 10 ng/ml IGF-I represented a physiological dose that would be able to bind to the IGFBPs, and would therefore be regulated by the level of IGFBPs present. The higher dose of 1 mg/ml IGF-I was designed to swamp the IGFBPs present, allowing IGF-I to bypass the regulatory mechanisms and hence bind freely to IGF receptors. Plates were incubated for 2, 4 or 6 days in a sterile humidified atmosphere with 5% CO 2 at 37 8C. Half of the culture medium was replaced every day, and this conditioned medium was stored at 220 8C for subsequent oestradiol analyses. Follicle diameters were measured with a crossed micrometer (basement membrane to basement membrane) under the dissection microscope.
Histological assessment
At the end of the culture period, follicles were fixed in 4% paraformaldehyde and dehydrated in graded alcohols, embedded in paraffin wax, sectioned at 6 mm thickness and mounted on Superfrost Plus microscope slides (VWR International, Poole, UK). Oocyte health observations were made under the light microscopes. An oocyte was classed as degenerate if it was misshapen or contained no germinal vesicle, and healthy oocytes were classed by having normal morphology and an intact germinal vesicle.
Detection of oestradiol in culture medium
Medium from the three treatments groups in all size ranges of follicles was analysed for oestradiol content as previously described by Thomas et al. (2003) . Briefly, biotinylated oestradiol, follicle-conditioned medium, oestradiol standards and a 1:50 000 dilution of primary antibody, made up in 200 ml of assay buffer, was added to precoated wells of the microtitre plate incubated overnight at 4 8C and then washed ( £ 4) in a wash buffer before addition of 100 ml assay buffer containing 100 ng/ml europium-labelled streptavidin (Perkin-Elmer Life Sciences, Newcastle upon Tyne, UK) followed by incubation at room temperature for 1 h with shaking. The plates were washed ( £ 4) in wash buffer before addition of 200 ml DELFIA enhancement solution (Perkin-Elmer Life Sciences) to each well of the microtitre plate, and incubated for a further 5 min with shaking at room temperature. The plates were analysed by time-resolved fluorimetry. The emission and excitation wavelengths were 615 and 340 nm respectively with a time delay of 400 ms. The inter-and intra-assay coefficients of variation were 13.2 and 9.6% respectively. The minimum detectable level was 8.5 pg oestradiol per well.
Immunohistochemistry
The expression of IGFBP-2 was detected in follicles cultured for 6 days. Antigen retrieval was performed by placing fixed sections (4 mm) in 0.01 M citrate buffer (2 £ 5 min (600 W)), and slides were left for 20 min at room temperature before being washed in PBS (2 £ 5 min). Endogenous peroxidase was blocked by placing sections in 1% hydrogen peroxide for 10 min, followed by washing (2 £ 5 min in PBS). The rabbit antibovine IGFBP-2 antiserum (Upstate Biotechnology, Lake Placid, NY, USA) was diluted 1:200 before use. After probing with primary antibody, the sections were washed and stained with goat antirabbit IgG labelled with horseradish peroxidase (1:100) (Sigma). Replacing primary antibody with normal rabbit serum, or saturating the primary antibody with antigen (recombinant bovine IGFBP-2 (31 kDa) (1 ng/ml) (GroPep, Adelaide, Australia)), detected non-specific binding. Furthermore, immunoblotting by the IGFBP-2 antibody revealed that it detected native IGFBP-2 added to medium and, furthermore, picked up only one band in bovine follicular fluid whose molecular mass corresponded to that of IGFBP-2.
In situ hybridisation
Details of the procedure used have been described by Armstrong et al. (1998 Armstrong et al. ( , 2002 . The expression of IGFBP-2 was detected in follicles in all size ranges, cultured for 2, 4 and 6 days. Sections (6 mm) were dehydrated, fixed and probed with 35 S-labelled IGFBP-2 riboprobe. After the final high stringency wash, the sections were dipped in autoradiographic K2 photographic emulsion (Ilford, Mobberley, UK) and exposed for 6 weeks at 4 8C. Sections were developed (Kodak D-19, Edinburgh, UK) and fixed with Hypam (Ilford) before staining in haematoxylin and eosin. The sections were finally mounted in DPX mountant (R A Lamb, Eastbourne, UK) before microscopic examination by both light-and dark-field illumination.
Image analysis
The intensity of the in situ hybridisation signal was analysed by the NIH Image system (National Institutes of Health, Bethesda, MD, USA). The number of graphic pixels occupied by silver grains (identified by a set grey threshold) within a defined area of the tissue section was counted and presented as a percentage of the total pixel number within the defined area. The hybridisation intensity, therefore, was the percentage of occupied pixels to total pixels within a defined area of the tissue. Background hybridisation intensity, measured with the sense RNA probes, was subtracted from the measurements obtained with the antisense probes to give the final hybridisation signal. Within each follicle, three separate fields (for granulosa cells) were analysed.
Immunohistochemistry analysis
The section containing the oocyte nucleolus or, if this was absent, the largest cross-section of the oocyte was used for observations. The total number of granulosa cells showing staining and no staining for IGFBP-2 protein was recorded for each follicle. The number of granulosa cells expressing IGFBP-2 protein was expressed as a percentage of the total granulosa cells present for each follicle. No significant difference was found between treatment groups in the mean percentage of granulosa cells exhibiting staining for IGFBP-2 protein. Therefore, the actual total number of follicles showing expression for IGFBP-2 in their granulosa cells or oocyte was calculated as a percentage of the total number of follicles analysed, and comparisons were made between treatment groups.
Statistical analysis
Mean follicle diameters and oestradiol production for each day were compared between experimental groups by repeated-measures ANOVA (general linear model), with subsequent Tukey's test for individual comparisons between groups. The intensity of staining for mRNA IGFBP-2 in granulosa cells was compared between days and treatment groups by ANOVA.
The total number of follicles exhibiting staining for IGFBP-2 protein, and those showing no staining for IGFBP-2 protein in their granulosa cells or oocytes in each treatment group, was also recorded. The number of follicles showing staining for IGFBP-2 protein in their granulosa cells or oocytes was calculated as a percentage of the total number of follicles and displayed as bar charts. Percentages were compared by two-proportion (test and confidence interval) analysis.
Results
Follicle growth
There was a significant increase in follicular diameter during culture in all treatment groups (P , 0.01). Follicles in the smallest size range (165-215 mm) cultured in the presence of 1 mg/ml IGF-I showed a significant increase in follicle diameter by day 4 compared with follicles cultured in the control medium (P , 0.01). There was no significant difference in follicle growth found between treatment groups within the other two size ranges of follicles (216-280 and 281-380 mm) (Fig. 1a -c) .
Oestradiol production
Oestradiol production increased significantly in all treatment groups during culture (P , 0.01). A significant increase in oestradiol production was observed by day 6 in all of the size ranges, in follicles cultured in the presence of 1 mg/ml IGF-I (P , 0.05) (Fig. 2a-c) . This significant increase in oestradiol production brought about by the presence of 1 mg/ml IGF-I was related to the size of the follicles; the largest follicles (281-380 mm) exhibited the increase faster than the medium-sized follicles (216-280 mm), and the medium-sized follicles showed the increase sooner than the smallest (165-215 mm) follicles.
Oocyte health
No significant difference in the percentage of degenerate oocytes was observed in the two size ranges, 165-215 and 216-280 mm. The percentage of follicles containing degenerate oocytes at the end of the culture was significantly higher in the largest size range (281-380 mm) cultured in the control treatment group than in day-0, 10 ng/ml IGF-I and 1 mg/ml IGF-I (P , 0.05) treatment groups (Fig. 3) .
Effect of IGF-I on the level of expression of IGFBP-2 (mRNA) in granulosa cells and oocytes mRNA IGFBP-2 was observed in the granulosa cells and oocyte of follicles on all days, in all treatment groups and in all size ranges (Fig. 4) . Initial analysis showed that there was no significant difference (P . 0.05) in hybridisation intensity between days or treatment groups. Therefore, the effect of IGF-I on IGFBP-2 protein production was studied.
Effect of IGF-I on the percentage of follicles expressing IGFBP-2 (protein) in their granulosa cells
IGFBP-2 immunoreactivity was observed in the granulosa cells of follicles in all size ranges (Fig. 5) . Follicles in the smallest size range (165-215 mm) were found not to have a significant difference in the percentage of follicles expressing IGFBP-2 in their granulosa cells. However, a significant decrease in IGFBP-2 expression was found in medium follicles cultured in 1 mg/ml IGF-I compared with the level of expression seen in the day-0 follicles (P , 0.05). Furthermore, in the largest size range (281-380 mm), there was a significant decrease in the Figure 1 Growth of bovine antral follicles, size ranges (a) 165-215 mm (n ¼ 123), (b) 216-280 mm (n ¼ 128) and (c) 281-380 mm (n ¼ 105), cultured in control medium (S), or in the presence of human recombinant IGF-I 10 ng/ml (B) or 1 mg/ml (O). Values are mean^S.E.M. By the end of the culture (day 6), follicles in the smallest size range, cultured in the presence of 1 mg/ml IGF-I, showed a significant (*) increase in follicle diameter compared with follicles cultured in control medium or in the presence of 10 ng/ml IGF-I. number of follicles expressing IGFBP-2 in the control and 10 ng/ml IGF-I treatment groups compared with that seen in the day-0 experimental group (P , 0.05). Follicles cultured with 1 mg/ml IGF-I were found to maintain the level of expression seen in the day-0 follicles, and therefore had a significantly higher percentage of follicles expressing IGFBP-2 than those seen in the control and 10 ng/ml IGF-I treatment groups (P , 0.05) (Fig. 6) .
Effect of IGF-I on the percentage of follicles expressing IGFBP-2 (protein) in their oocytes
IGFBP-2 immunoreactivity was observed in the oocytes of follicles in all size ranges (Fig. 5) . No significant difference was found between treatment groups in the percentage of follicles expressing IGFBP-2 in their oocytes in follicle groups with a small and medium-size range (165-215 and 216-280 mm). However, a significant decrease in IGFBP-2 expression was found in the largest size range (281-380 mm) of follicles cultured in the control or 10 ng/ml IGF-I treatment groups (P , 0.01) (Fig. 7) . and 216 -280 mm was observed. However, follicles in the larger size range (281-380 mm) cultured in control medium had significantly more degenerate oocytes than day-0, 10 ng/ml IGF-I and 1 mg/ml IGF-I (P , 0.05) treatment groups. Different superscripts denote statistically significant differences (P , 0.05). 
Discussion
Previous work has outlined the involvement of IGFBP-2 in the regulation of IGF-I bioavailability (Perks & Wathes 1996 , Armstrong et al. 1998 , Yuan et al. 1998 , Monget et al. 2002 . It has been hypothesised that IGFBP-2 present in early stages of follicle growth will bind any IGF arriving from the circulation or adjacent antral follicles and regulate its access to the type 1 IGF receptors found in the oocytes and granulosa cells (Armstrong et al. 2002) . This study has confirmed that IGFBP-2 (mRNA and protein) is expressed in the oocytes and granulosa cells of early antral follicles. The novel use of varying concentrations of IGF-I as a way to bypass the IGFBPs has highlighted a key role for IGF-I at this stage of follicular development in both granulosa cell differentiation and proliferation. In addition, the level of IGF-I available to a follicle can have a direct affect on the level of expression of IGFBP-2, and hence the availability of IGF-I. Furthermore, these regulatory effects appear to be dependent on the stage of follicle development. Since the type 1 IGF receptor is present in oocytes and granulosa cells of bovine preantral and early antral follicles (Armstrong et al. 2000) , removal of the regulatory influence of IGFBP-2 in vitro may allow a direct action of IGF-I on the developing follicle. In this study, the follicles cultured in medium supplemented with 1 mg/ml IGF-I would be expected to be exposed to the actions of IGF-I, as, at this concentration, the regulation of IGF-I by its binding proteins would be bypassed, and IGF-I would have the potential to act via the IGF receptors. It is likely that high concentrations of IGF-I, while swamping the IGFBPs, would also downregulate the type 1 IGF receptors. Recombinant IGF-I increases bovine preantral follicle and oocyte diameter in vitro (Itoh et al. 2002) , and long R3-IGF-I (LR3 IGF-I), an analogue which does not bind to binding proteins, has aided in the formation of the antrum . However, it is evident that regulation by IGFBPs of IGF-I is beneficial for normal oocyte development in preantral follicles, as inappropriate exposure of preantral follicles to IGF-I has detrimental Values are the mean percentage of follicles showing staining for IGFBP-2 in their granulosa cells for each treatment group within each size range. A significant decrease was found in the follicles cultured in 1 mg/ml IGF-I with a size range of 216-280 mm (P , 0.05). Follicles in the size group 281-380 mm showed a decrease in IGFBP-2 expression when cultured in the control or 10 ng/ml IGF-I treatment groups (P , 0.05). Follicles cultured with 1 mg/ml IGF-I had a significantly higher level of expression than that seen in the control and 10 ng/ml IGF-I treatment groups (P , 0.05). Different superscripts denote statistically significant differences (P , 0.05). effects on oocyte health (McCaffery et al. 2000) . In addition to IGFs exerting an action through their own receptors, under certain conditions they can also exert an action via insulin receptors (Hwa et al. 1999) , although this interaction is of a lower affinity than that of insulin for its own receptor. Under certain circumstances, the insulin receptor may mediate some of the biological actions of the IGFs (Hwa et al. 1999 , LeRoith 2000 . The IGF-I receptors would have been overwhelmed by IGF-I when the high dose (1 mg/ml) of IGF-I was present. Therefore, a possible hypothesis is that, under these conditions, the IGF-I may have been able to mediate its actions via the insulin receptors, as well as the type 1 IGF receptor. This would explain the significant stimulatory effect on the growth of the early antral follicles in the size range 165-215 mm and the significant increase in oestradiol production seen in all size ranges of follicles. Hence, elucidation of the mechanisms involved in controlling the expression of IGFBPs during late preantral/early antral follicle development would be beneficial when developing in vitro culture systems for mammalian follicles.
We have shown here that the growth of follicles at an immature stage of development is influenced by direct access to IGF-I; however, the more mature follicles are unaffected by the exposure to IGF-I. Follicles at all stages of development exhibit a significant increase in oestradiol production, with the most mature follicles showing the increase earliest in culture. This implies that, as the follicles mature, they undergo rapid differentiation rather than proliferation, thereby increasing oestradiol production and aiding their chance of escaping follicular atresia. Previous work on bovine ovarian function has found the effect of IGF-I to be influenced by the differentiated state of the follicle (Gutierrez et al. 1997) . IGF-I has been shown to stimulate oestradiol production by granulosa cells from small antral follicles (,4 mm in diameter), whereas oestradiol production was not stimulated in granulosa cells from large follicles (4 -8 and $ 8 mm in diameter) (Gutierrez et al. 1997) . However, oestradiol production in granulosa cells from ovine antral follicles (from 2 to $ 3.5 mm in diameter) was found to be stimulated by IGF-I at concentrations of 1 and 10 ng/ml but suppressed at the higher dose of 100 ng/ml .
IGF-I is known to stimulate nuclear maturation of cumulus-enclosed oocytes (Lorenzo et al. 1994 , Sirotkin et al. 2000 and improve early embryonic development (Pawshe et al. 1998 . However, in contrast to work carried out previously on bovine preantral follicles -in which the LR3 IGF-I analogue (which does not bind to IGFBPs) was found to have a detrimental effect on oocyte health (McCaffery et al. 2000) -IGF-I was not found to have a detrimental effect on oocyte health at this later developmental stage. In fact, the presence of IGF-I even at the high concentration was found to be beneficial in maintaining oocyte health once the follicle has reached a more mature stage of development (antral follicles with a follicle diameter of 281-380 mm).
IGFBP expression has been found to be influenced by the presence of various hormones and growth factors (Sakal et al. 1992 , Chamberlain & Spicer 2001 , Voge et al. 2004 . In particular, IGF has been shown to play a role in the control of ovine granulosa cell IGFBP-2 production, in which both FSH and IGF-I are necessary for maximum production of IGFBP-2 (Armstrong et al. 1996) . Grimes and Hammond (1992) showed that IGF-I in a dosedependent manner significantly stimulated the production of IGFBP-2 and -3 in granulosa cells taken from porcine follicles 4 -6 mm in diameter. Furthermore, the synthetic analogue, LR3-IGF-I, which has a low affinity for IGFBPs, was shown to have a significantly greater potency in stimulating the production of these IGFBPs than IGF-I. Taken together, these results suggest that IGFBP production is regulated by the type 1 IGF receptor, and that an increase in IGF activity stimulates the production of IGFBPs, which in turn reduces the bioavailability of the IGFs. The results found in this current study (summarised in Table 1) support the finding that IGF-I can stimulate IGFBP-2 expression in a dose-dependent manner. It was found that the percentage of follicles expressing IGFBP-2 in their granulosa cells in the largest size group decreased when IGF-I was absent or the concentration present was low. By contrast, when the follicles were cultured in a high Table 1 Summary of the effect of human recombinant IGF-I on follicle proliferation, differentiation and IGFBP-2 (protein) expression in early antral bovine ovarian follicles cultured in vitro. concentration of IGF-I, the high level of expression of IGFBP-2 found in the day-0 follicles was maintained. A possible explanation of these results is that at this stage in development the granulosa cells have differentiated enough to be able to respond to the action of IGF-I by adjusting the expression of IGFBP-2, possibly by a negative feedback mechanism. Furthermore, the oocyte appears to have also developed to a stage where it too can modulate the expression of IGFBP-2 to regulate IGF bioavailability. However, further investigation is required, as the effect of the high concentration of IGF-I on IGFBP-2 could have been mediated via the insulin receptors and thus be an insulin effect.
In conclusion, the stimulatory effects of IGF-I on early bovine follicle proliferation, differentiation and oocyte health were found to be dose and stage dependent. It is now clear that the biological actions of IGF depend in part on the ability of specific proteases to break down the IGF/IGFBP complex and/or the level of expression of the IGFBPs (Giudice 1992) . This work has shown that IGF-I can play a role in regulating its own bioavailability by influencing the expression of IGFBP-2. These results suggest that IGF-I may do this through a negative feedback mechanism, which again is stage dependent. The control of local growth factors by regulatory mechanisms needs to be more fully investigated, as it appears to be the key in developing an in vitro culture system that will accelerate follicle development without causing precocious differentiation to occur.
